Linked Life Data

18362913

Source:http://linkedlifedata.com/resource/pubmed/id/18362913

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2009-10-23
pubmed:abstractText
There is an increasing interest in the underlying mechanisms of the antidepressant and anxiolytic treatment effect associated with changes in serotonergic neurotransmission after treatment with selective serotonin (5-HT) reuptake inhibitors (SSRIs) in humans. The 5-HT(1A) receptor is known to play a crucial role in the pathophysiology of affective disorders, and altered 5-HT(1A) receptor binding has been found in anxiety patients. SSRI treatment raises the 5-HT level in the synaptic cleft and might change postsynaptic receptor densities. Therefore, our study in patients suffering from anxiety disorders investigated the effects of long-term treatment with escitalopram on the 5-HT(1A) receptor. A longitudinal positrone emission tomography (PET) study in 12 patients suffering from anxiety disorders was conducted. Two dynamic PET scans were performed applying the selective 5-HT(1A) receptor antagonist [carbonyl-(11)C]WAY-100635. Eight regions of interest were defined a priori (orbitofrontal cortex, amygdala, hippocampus, subgenual cortex, anterior and posterior cingulate cortex, dorsal raphe nucleus and cerebellum as reference). After the baseline PET scan, patients were administered escitalopram (average dose of 11.2+/-6.0 mg day(-1)) for a minimum of 12 weeks. A second PET scan was conducted after 109+/-27 days. 5-HT(1A) receptor binding potentials in 12 patients were assessed by PET applying the Simplified Reference Tissue Model.There was a significant reduction in the 5-HT(1A) receptor binding potential after a minimum of 12 weeks of escitalopram treatment in the hippocampus (P=0.006), subgenual cortex (P=0.017) and posterior cingulate cortex (P=0.034). The significance of the hippocampus region survived the Bonferroni-adjusted threshold for multiple comparisons. These PET data in humans in vivo demonstrate a reduction of the 5-HT(1A) binding potential after SSRI treatment.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1476-5578
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1040-50
pubmed:meshHeading
pubmed-meshheading:18362913-Adult, pubmed-meshheading:18362913-Antidepressive Agents, Second-Generation, pubmed-meshheading:18362913-Anxiety, pubmed-meshheading:18362913-Brain Mapping, pubmed-meshheading:18362913-Carbon Isotopes, pubmed-meshheading:18362913-Case-Control Studies, pubmed-meshheading:18362913-Citalopram, pubmed-meshheading:18362913-Clinical Trials as Topic, pubmed-meshheading:18362913-Female, pubmed-meshheading:18362913-Follow-Up Studies, pubmed-meshheading:18362913-Humans, pubmed-meshheading:18362913-Limbic System, pubmed-meshheading:18362913-Magnetic Resonance Imaging, pubmed-meshheading:18362913-Male, pubmed-meshheading:18362913-Middle Aged, pubmed-meshheading:18362913-Piperazines, pubmed-meshheading:18362913-Positron-Emission Tomography, pubmed-meshheading:18362913-Protein Binding, pubmed-meshheading:18362913-Pyridines, pubmed-meshheading:18362913-Receptor, Serotonin, 5-HT1A, pubmed-meshheading:18362913-Serotonin Antagonists, pubmed-meshheading:18362913-Time Factors, pubmed-meshheading:18362913-Young Adult
pubmed:year
2009
pubmed:articleTitle
Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders.
pubmed:affiliation
Department of Psychiatry and Psychotherapy, Medical University Vienna, Vienna, Austria.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't